Katsumata N, Eguchi K, Fukuda M, Yamamoto N, Ohe Y, Oshita F, Tamura T, Shinkai T, Saijo N
Department of Medical Oncology, National Cancer Center Hospital, and Division of Pharmacology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104, Japan.
Clin Cancer Res. 1996 Mar;2(3):553-9.
To evaluate the relationships between serum endogenous cytokine levels and their clinical implications in cancer patients, we measured the serum levels of endogenous granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), and interleukin 6 (IL-6) in patients with untreated primary lung cancer. The serum G-CSF level was measured using a chemiluminescent ELISA, and the other cytokine levels were measured using ELISA. Fifty healthy adults and 183 patients with primary lung cancer were studied. The mean M-CSF level in the lung cancer patients (1106.4 units/ml) was significantly higher than that in the healthy adults (836 units/ml, P = 0.0001). In patients with large cell carcinoma, endogenous G-CSF, M-CSF, and IL-6 levels were significantly higher than those in patients with carcinomas of other cell types (P < 0.05). Univariate analysis showed that survival of 159 non-small cell lung cancer patients with high (more than cutoff level) G-CSF, M-CSF, and IL-6 levels was significantly poorer than that of patients with low levels (Wilcoxon's test, P = 0.018, P < 0. 0001, and P < 0.0001, respectively). Survival of patients with high levels of two or more cytokines was poorer than that of those with high levels of one cytokine or normal cytokine levels (P < 0.0001). Multivariate analysis using Cox's proportional hazards model showed that high M-CSF and C-reactive protein levels correlated significantly with poor survival (P = 0.037 and 0.037, respectively). Our preliminary data suggest that high M-CSF levels in non-small cell lung cancer may be of poor prognostic value.
为了评估癌症患者血清内源性细胞因子水平与其临床意义之间的关系，我们检测了未经治疗的原发性肺癌患者血清中内源性粒细胞集落刺激因子（G-CSF）、粒细胞-巨噬细胞集落刺激因子（GM-CSF）、巨噬细胞集落刺激因子（M-CSF）和白细胞介素6（IL-6）的水平。血清G-CSF水平采用化学发光酶联免疫吸附测定法检测，其他细胞因子水平采用酶联免疫吸附测定法检测。研究对象为50名健康成年人和183名原发性肺癌患者。肺癌患者的平均M-CSF水平（1106.4单位/毫升）显著高于健康成年人（836单位/毫升，P = 0.0001）。在大细胞癌患者中，内源性G-CSF、M-CSF和IL-6水平显著高于其他细胞类型癌患者（P < 0.05）。单因素分析显示，159名G-CSF、M-CSF和IL-6水平高（超过临界水平）的非小细胞肺癌患者的生存率显著低于水平低的患者（分别为Wilcoxon检验，P = 0.018、P < 0.0001和P < 0.0001）。两种或更多细胞因子水平高的患者的生存率低于一种细胞因子水平高或细胞因子水平正常的患者（P < 0.0001）。使用Cox比例风险模型进行的多因素分析显示，高M-CSF和C反应蛋白水平与不良生存率显著相关（分别为P = 0.037和0.037）。我们的初步数据表明，非小细胞肺癌中高M-CSF水平可能具有不良预后价值。
